Zhu-Jun Deng

Zhu-Jun Deng

Auto-generated profile, based on publicly available information

Zhu-Jun Deng

Precision Medicine Center

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Disease Markers
Verified
Journal Article
Open access
PDF file
JWJing Wang
Jing Wang
ZDZhujun Deng
Zhujun Deng
XLXiaoqiang Lang
Xiaoqiang Lang
JJJuan Jiang
Juan Jiang
KXKang Xie
Kang Xie
WZWengeng Zhang
Wengeng Zhang
Background. Various studies have produced contradictory results on the prognostic role of the CpG island methylator phenotype (CIMP) among colorectal cancer (CRC) patients. Although a meta-analysis published in 2014 reported a worse prognosis of CIMP among CIMP-high (CIMP-H) CRC patients, the sample sizes of the major included studies were small. In this study, we included the most recent studies with large sample sizes and performed an updated meta-analysis on the relationship between CIMP and CRC prognosis. Methods. A search of MEDLINE, Web of Science, and Cochrane for studies related to CIMP and CRC published until July 2021 was conducted based on the PICO (participant, intervention, control, outcome) framework. Data extraction and literature analyses were performed according to PRISMA standards. Results. In the present update, 36 eligible studies (20 recently published) reported survival data in 15315 CRC patients, 18.3% of whom were characterized as CIMP-H. Pooled analysis suggested that CIMP-H was associated with poorer overall survival (OS) ( , 95% CI: 1.26–1.48) and disease-free survival/progression-free survival/recurrence-free survival (DFS/PFS/RFS) ( , 95% CI: 1.19–1.91) among CRC patients. Subgroup analysis based on tumor stage and DNA mismatch repair (MMR) status showed that only patients with stages III-IV and proficient MMR (pMMR) tumors showed a significant association between CIMP-H and shorter OS, with HRs of 1.52 and 1.37, respectively. Three studies were pooled to explore the predictive value of CIMP on CRC patient DFS after receiving postoperative chemotherapy, and no significant correlation was found. Conclusion. CIMP-H is associated with a significantly poor prognosis in CRC patients, especially those with stage III-IV and pMMR tumors. However, the predictive value of CIMP needs to be confirmed by more prospective randomized studies.

8 February 2014 in Ophthalmologica
Verified
Journal Article
Closed access
PDF file
ZDZhu-Jun Deng
Zhu-Jun Deng
KSkeqing shi
keqing shi
YSYi-Jiang Song
Yi-Jiang Song
YFYu-Xiao Fang
Yu-Xiao Fang
JWJianmin Wu
Jianmin Wu
JQJia Qu
Jia Qu
Purpose: To evaluate the relationship between lumican polymorphisms and high myopia in Chinese populations. Methods: An electronic search was conducted in Pubmed, Embase, Cochrane Library and the China Biological Medicine Database for articles published prior to September 30, 2012. A meta-analysis was performed to assess heterogeneity, combine results and determine publication bias. Results: This meta-analysis, including 1,545 subjects from 5 studies, indicated that Chinese lumican rs3759223 C allele carriers had a decreased risk of high myopia in comparison to T allele carriers (odds ratio: 0.531; 95% confidence interval, CI: 0.304-0.925; p = 0.025). There was some heterogeneity between studies. A metaregression showed that the mean axial length of controls weakens the effect of rs3759223 on high myopia (slope: -0.914; 95% CI: -1.490 to 0.337; p = 0.002). Sensitivity analysis confirmed the reliability and stability of this meta-analysis. Conclusion: Chinese lumican rs3759223 C allele carriers may be at reduced risk of high myopia.